Year 2023 / Volume 115 / Number 3
Editorial
How strong is the evidence to support statins repurposing for the treatment of cirrhosis?

107-109

DOI: 10.17235/reed.2022.9281/2022

Carlos Moctezuma-Velázquez, Juan G. Abraldes,

Abstract
In this editorial, we briefly mention the studies that support the use of statins to change the natural history of liver cirrhosis, alongside potential biases and flaws that need to be considered when analyzing data. The key message that we want to communicate is that even if current evidence is somehow compelling, it is limited, mostly from observational studies, and in general not enough to formally recommend the prescription of statins in patients with cirrhosis as disease-modifying agents. Finally, we also mention some important facts about the safety of statins in the context of patients with underlying liver disease.
Share Button
New comment
Comments
No comments for this article
References
1 Bosch J, Gracia-Sancho J, Abraldes JG. Cirrhosis as new indication for statins. Gut. 2020;69(5):953-62.
2 Gu Y, Yang X, Liang H. Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis. BMC Gastroenterol. 2019;19(1):231.
3 Alvarado-Tapias E, Montanes R, Brujats A, et al. Carvedilol plus Simvastatin modulates systemic inflammation in cirrhosis with portal hypertension and non-response to B-blockers: randomised double-blind study. Journal of Hepatology. 2022;77:S91.
4 de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959-74.
5 Abraldes JG, Villanueva C, Aracil C, et al. Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. Gastroenterology. 2016;150(5):1160-70.e3.
6 Young NS, Ioannidis JP, Al-Ubaydli O. Why current publication practices may distort science. PLoS Med. 2008;5(10):e201.
7 Meireles CZ, Pasarin M, Lozano JJ, et al. Simvastatin Attenuates Liver Injury in Rodents with Biliary Cirrhosis Submitted to Hemorrhage/Resuscitation. Shock. 2017;47(3):370-7.
8 Caraceni P, Abraldes JG, Ginès P, et al. The search for disease-modifying agents in d ecompensated cirrhosis: From drug repurposing to drug discovery. J Hepatol. 2021;75 Suppl 1:S118-S34.
9 Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013(1):CD004816.
10 Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089-98.
11 Verma S, McGuire DK, Bain SC, et al. Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials. Diabetes Obes Metab. 2020;22(12):2487-92.
12 Dickerman BA, García-Albéniz X, Logan RW, et al. Avoidable flaws in observational analyses: an application to statins and cancer. Nat Med. 2019;25(10):1601-6.
13 Yeh YC, Chen YY, Chen PC. Statins were not associated with hepatocellular carcinoma after controlling for time-varying confounders in patients with diabetes. J Clin Epidemiol. 2022;150:98-105.
14 Mahmud N, Chapin S, Goldberg DS, et al. Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort. J Hepatol. 2022.
15 Cnossen MC, van Essen TA, Ceyisakar IE, et al. Adjusting for confounding by indication in observational studies: a case study in traumatic brain injury. Clin Epidemiol. 2018;10:841-52.
16 Yun B, Ahn SH, Yoon JH, et al. Statin use and risk of progression to liver cirrhosis in chronic hepatitis B independent of conventional risk factors: A nationwide study. Hepatol Commun. 2022;6(9):2455-64.
17 Merkel M, Schneider C, Greinert R, et al. Protective Effects of Statin Therapy in Cirrhosis Are Limited by a Common SLCO1B1 Transporter Variant. Hepatol Commun. 2021;5(10):1755-66.
18 Chiu WC, Shan JC, Yang YH, et al. Statins and the risks of decompensated liver cirrhosis and hepatocellular carcinoma determined in patients with alcohol use disorder. Drug Alcohol Depend. 2021;228:109096.
19 Motzkus-Feagans C, Pakyz AL, Ratliff SM, et al. Statin use and infections in Veterans with cirrhosis. Aliment Pharmacol Ther. 2013;38(6):611-8.
20 Hung TH, Tsai CC, Lee HF. Statin use in cirrhotic patients with infectious diseases: A population-based study. PLoS One. 2019;14(4):e0215839.
21 Zou B, Odden MC, Nguyen MH. Statin Use and Reduced Hepatocellular Carcinoma Risk in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2022.
22 Kawaguchi Y, Sakamoto Y, Ito D, et al. Statin use is associated with a reduced risk of hepatocellular carcinoma recurrence after initial liver resection. Biosci Trends. 2017;11(5):574-80.
23 Ertefaie A, Small DS, Flory JH, et al. A tutorial on the use of instrumental variables in pharmacoepidemiology. Pharmacoepidemiol Drug Saf. 2017;26(4):357-67.
24 Pose E, Napoleone L, Amin A, et al. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Gastroenterol Hepatol. 2020;5(1):31-41.
25 Sung S, Al-Karaghouli M, Kalainy S, et al. A systematic review on pharmacokinetics, cardiovascular outcomes and safety profiles of statins in cirrhosis. BMC Gastroenterol. 2021;21(1):120.
Related articles

Editorial

Treatment of portal vein thrombosis in cirrhosis patients

DOI: 10.17235/reed.2023.9800/2023

Digestive Diseases Image

Spontaneous duodenal wall hematoma

DOI: 10.17235/reed.2023.9793/2023

Letter

Tolvaptan in portal hypertension: real life experience

DOI: 10.17235/reed.2022.9145/2022

Letter

Hemoperitoneum due to rupture of intra-abdominal varices

DOI: 10.17235/reed.2022.8937/2022

Digestive Diseases Image

Traumatic high flow arterioportal fistula. Correction by a covered stent

DOI: 10.17235/reed.2022.8724/2022

Letter

Cirrhotic pattern in advanced hepatic sarcoidosis

DOI: 10.17235/reed.2021.8446/2021

Digestive Diseases Image

Portal thrombosis in a patient with SARS-CoV-2 infection

DOI: 10.17235/reed.2021.8099/2021

Digestive Diseases Image

Portal pneumatosis in a patient with severe Salmonella colitis

DOI: 10.17235/reed.2021.8090/2021

Letter

Non-oclusive mesenteric ischemia as a complication of dialysis

DOI: 10.17235/reed.2021.7897/2021

Letter

Portal vein aneurysm, an update on the subject. A case report

DOI: 10.17235/reed.2020.6842/2019

Letter

Stomal varices: an unusual cause of bleeding in liver cirrhosis

DOI: 10.17235/reed.2020.6470/2019

Letter

Intestinal infection leads to hepatic portal venous gas.

DOI: 10.17235/reed.2019.6049/2018

Letter to the Editor

Idiopathic portal hypertension with regard to thiopurine treatment

DOI: 10.17235/reed.2018.5256/2017

Letter to the Editor

Abdominal compartment syndrome secondary to acute necrotizing pancreatitis

DOI: 10.17235/reed.2017.4810/2016

Letter to the Editor

POEMS syndrome and idiopathic portal hypertension: a possible association

DOI: 10.17235/reed.2017.4623/2016

Citation tools
Moctezuma-Velázquez C, Abraldes J. How strong is the evidence to support statins repurposing for the treatment of cirrhosis?. 9281/2022


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1203 visits.
This article has been downloaded 249 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 14/10/2022

Accepted: 22/10/2022

Online First: 10/11/2022

Published: 07/03/2023

Article revision time: 3 days

Article Online First time: 27 days

Article editing time: 144 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology